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Background. Ivermectin (IVM) has been the drug of choice for the treatment of onchocerciasis. However, there
have been reports of persistent microﬁlaridermia in individuals from an endemic area in Ghana after many rounds of
IVM, raising concerns of suboptimal response or even the emergence of drug resistance. Because it is considered
risky to continue relying only on IVM to combat this phenomenon, we assessed the effect of targeting the Oncho-
cerca volvulus Wolbachia endosymbionts with doxycycline for these individuals with suboptimal response.
Methods. One hundred sixty-seven patients, most of them with multiple rounds of IVM, were recruited in areas
with IVM suboptimal response and treated with 100 mg/day doxycycline for 6 weeks. Three and 12 months after
doxycycline treatment, patients took part in standard IVM treatment.
Results. At 20 months after treatment, 80% of living female worms from the placebo group were Wolbachia
positive, whereas only 5.1% in the doxycycline-treated group contained bacteria. Consistent with interruption of
embryogenesis, none of the nodules removed from doxycycline-treated patients contained microﬁlariae, and 97%
of those patients were without microﬁlaridermia, in contrast to placebo patients who remained at pretreatment levels
(P < .001). Moreover, a signiﬁcantly enhanced number of dead worms were observed after doxycycline.
Conclusions. Targeting the Wolbachia in O. volvulus is effective in clearing microﬁlariae in the skin of
onchocerciasis patients with persistent microﬁlaridermia and in enhanced killing of adult worms after repeated stan-
dard IVM treatment. Strategies can now be developed that include doxycycline to control onchocerciasis in areas
where infections persist despite the frequent use of IVM.
Clinical Trials Registration. ISRCTN 66649839.
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Onchocerciasis affects >37 million people and remains a
signiﬁcant public health burden in developing countries
[1, 2]. This infection is caused by the ﬁlarial nematode
Onchocerca volvulus, residing in subcutaneous nodules
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where they produce millions of microﬁlariae (Mf) during their
average life span of 10 years [3, 4]. The Mf migrate through the
skin and eyes and are responsible for disease, such as dermatitis
and visual impairment.
The African Programme for Onchocerciasis Control (APOC)
relies on ivermectin (IVM) mass drug administration (MDA).
However, the use of a single drug, of which more than a billion
doses could potentially be needed for disease elimination [5],
has raised concerns that adaptation of the parasites or the
hosts [6], a reduction in effectiveness of the drug, or even
drug resistance might occur and impair the success of the con-
trol programs. Resistance has occurred in several veterinary par-
asitic nematodes [7], and treatment failures have been suspected
in other human helminthic infections [8–10].
In 2004, suboptimal response (SOR) to IVMwas reported in on-
chocerciasis-endemic populations in communities of the Brong-
Ahafo Region of Ghana [11, 12] with signiﬁcant microﬁlaridermia
despite a history of multiple (up to 14) MDAs with IVM. This in-
dicates a considerable risk in continuing to rely on only increased
IVM interventions [13]. A better intervention could be a chemo-
therapy leading to adulticidal or long-term sterilizing effects on
the worms, at best with an already registered, repurposed drug.
Recently, our group has developed macroﬁlaricidal and long-
term-sterilizing regimens based on the depletion ofWolbachia en-
dosymbionts fromO. volvulus. We demonstrated that doxycycline
given at 100 mg/day for 5 or 6 weeks leads to a complete and ir-
reversible (>2 years) sterilization of adult female worms. There is
also a macroﬁlaricidal effect that can be ﬁrst observed with 100
mg/day treatment by 5 weeks [14] and that seems to be more pro-
nounced when doxycycline is administered at 200 mg/day [15].
Doxycycline is an antiﬁlarial treatment that is more effective
than the standard MDA regimen and is available to treat indi-
vidual patients [16]. To formally prove the suitability of doxy-
cycline in areas where MDA with IVM shows suboptimal
performance, we carried out a placebo-controlled, double-
blind, randomized study with 100 mg/day doxycycline admin-
istered for 6 weeks to patients with onchocerciasis in an area
with multiple documented rounds of IVM treatment.
METHODS
Study Population and Area, Subject Eligibility, and Selection
The study was undertaken in 13 onchocerciasis-endemic com-
munities located along the Pru, Lower Black Volta, and Tain
river basins in the Brong-Ahafo Region of Ghana and includes
communities where IVM SOR was reported [17, 18]. This study
was approved by the Committee on Human Research, Publica-
tions and Ethics of the School of Medical Sciences of the
Kwame Nkrumah University of Science and Technology,
Kumasi, Ghana, and is registered at Current Controlled Trials
(www.isrctn.com, identiﬁer 66649839).
Volunteers were screened using the Onchocerciasis Control
Programme registration books in combination with question-
naires to select those having microﬁlariae in the skin despite
multiple previous treatments, and/or reappearance of palpable
nodules [12]. Eligible volunteers had taken on average 10 rounds
of IVM and 86% of the study participants had received ≥7 rounds
(Table 1). Eligible participants were nodule carriers aged 18–50
years, >40 kg body weight, in good health, and without clinical
conditions requiring chronic medication. Hepatic and renal func-
tions as well as pregnancy tests were assessed by dipstick chemis-
try using venous blood and urine. Skin snips (biopsies) were taken
to determine skin microﬁlarial loads. Exclusion criteria were ab-
normal hepatic and renal enzymes, pregnancy, breastfeeding,
intolerance to doxycycline, alcohol or drug abuse, history of
tuberculosis, glucose in urine, hypertension, or history of any con-
dition requiring long-termmedication (see also ISRCTN registry).
Study Design, Randomization, and Interventions
The primary objective of this randomized, placebo-controlled,
double-blind trial was to assess the macroﬁlaricidal or sterilizing
effect of doxycycline on adult femaleO. volvulus worms. Sample
size was calculated based on the proportion of dead female
O. volvulus worms observed in a previous study on doxycycline
treatment [15]. Assuming a rate of 30% of patients with dead
female worms in the placebo group and a rate of 62% in the
doxycycline group, Fisher exact test (2-sided) at the level of
α = 5% had a power of at least 90% with a sample size of 55 pa-
tients per study group. Allowing a dropout rate of 33%, the total
number of patients per treatment arm was 83 individuals. To
assure an equal distribution of Mf-positive and Mf-negative
individuals to the treatment groups, eligible patients were ran-
domized separately according to their Mf status by computer-
generated random allocation sequence.
Participants received 100 mg doxycycline (Doxydoc) or
matching placebo per day for 6 weeks under daily observation.
Participants were instructed to continue participating in the on-
going MDA at 3 and 13 months after treatment. After study
completion, doxycycline was offered to all placebo group partic-
ipants and the Mf-positive patients from the doxycycline group.
Nodule Mapping
The palpable nodules were mapped at study entry and at 20
months immediately prior to operation; the locations were as-
signed to a standardized system (head, shoulder, thorax, iliac
crest, trochanter, os sacrum, knees). At 20 months, all palpable
nodules were removed from the available patients.
Laboratory Procedures
Skin Mf were assessed before and at 12 and 20 months after
treatment onset. Two skin biopsies of 1–3 mg were taken
from the buttocks and prepared for microscopic examination,
as described previously [15].
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Nodules were ﬁxed in 80% ethanol and embedded in
parafﬁn, and sections were stained with hematoxylin and
eosin or Gomori method for iron, or immunostained against
Diroﬁlaria immitis Wolbachia surface protein (Diwsp) and
cathepsin D–like lysosomal aspartic protease of O. volvulus
[15]. At least 8 sections across the nodules were histologically
assessed. Worms that had been acquired after treatment
according to the deﬁnition described previously [4] were
subtracted from all analyses. Worms were classiﬁed as
newly acquired, young, middle-aged, or old [19]. Sections
were assessed independently by 2 experienced parasitologists
(S. S., C. D. M.).
Table 1. Patient Baseline Data
Characteristic
Treatment
Doxycycline Placebo P Value
No. of patients 84 83
Age, y P= .004a
Mean ± SD 35.45 ± 9.46 39.60 ± 9.08
Weight, kg P= .079a
Mean ± SD 59.44 ± 8.25 57.23 ± 7.89
Sex, No. P= .289b
Female 18 (21.4%) 24 (28.9%)
Male 66 (78.6%) 59 (71.1%)
IVM rounds P= .461c
Mean ± SD 10.40 ± 3.52 10.72 ± 3.36
Min–Max 4–17 0–17
Median 10 10
25th, 75th percentiles 7.0, 13.8 9.0, 13.0
No. of rounds
0 0 (0%) 1 (1.2%)
4 3 (3.6%) 2 (2.4%)
5 3 (3.6%) 3 (3.6%)
6 8 (9.5%) 4 (4.8%)
7 8 (9.5%) 3 (3.6%)
8 3 (3.6%) 3 (3.6%)
9 10 (11.9%) 8 (9.6%)
10 9 (10.7%) 18 (21.7%)
11 9 (10.7%) 11 (13.3%)
12 8 (9.5%) 7 (8.4%)
13 2 (2.4%) 3 (3.6%)
14 7 (8.3%) 7 (8.4%)
15 8 (9.5%) 8 (9.6%)
16 2 (2.4%) 1 (1.2%)
17 4 (4.8%) 4 (4.8%)
No. of palpated nodules P= .279c
Total No. 206 198
Mean ± SD 2.45 ± 1.41 2.39 ± 1.79
Median 2 2
No. of palpated sites P= .339c
Total No. 136 127
Mean ± SD 1.62 ± 0.79 1.53 ± 0.80
Median 1 1
Abbreviations: IVM, ivermectin; SD, standard deviation.
a Student t test.
b Fisher exact test.
c Mann–Whitney U test.
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Statistical Methods
Differences between the 2 treatment groups were analyzed with
Student t test for quantitative parametric and the Mann–Whitney
U test for all other nonparametric variables. Fisher exact test was
used to compare binary qualitative variables and the Spearman
rank correlation for comparisons of 2 quantitative parameters.
Quantitative baseline values were compared to follow-up values
using the sign test. Histological results were tested on single
worm and on patient levels using the Mann–Whitney U test for
quantitative and Fisher exact test for qualitative data. In addition,
regression analyses were performed using alternating logistic regres-
sion, as implemented in the SAS procedure Genmod. This proce-
dure allows testing for a potential dependency between the worms
in 1 patient. Four data sets (per protocol [PP]; intention to treat
[ITT]; treatment-PP; treatment and IVM-PP) were used to analyze
the data and are explained in the relevant tables. Analyses were
done using SPSS (IBM SPSS Statistics 22; Armonk, New York)
and SAS version 9.2 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Participant Flow and Adverse Reactions
The trial proﬁle of the study is illustrated in Supplementary
Figure 1. In all, 167 volunteers were enrolled and subsequently
randomized into the treatment arms. Baseline data are given in
Table 1. Importantly, 86% of study participants had taken ≥7
rounds of IVM (average 10 rounds). Statistical analysis showed
that not only the Mf positivity (P = .86; ITT) but also the inten-
sity of microﬁlaridermia (Mf/mg skin; P = .35; ITT) was inde-
pendent of the IVM intake, consistent with the ﬁnding of
suboptimal responses to IVM. Adherence to treatment was gen-
erally high. Doxycycline was well tolerated, with only mild
adverse reactions (ARs) encountered (Supplementary Table 1).
Twenty individuals (13 doxycycline, 7 placebo) did not com-
plete the treatment course. Eleven patients (7 doxycycline, 4
placebo) dropped out because they reported ARs, such as diar-
rhea and vomiting, that the code-blinded medical doctors could
not exclude from being potentially related to drug intake; all
the other reasons for incompletion were reported as not drug-
related. There was no signiﬁcant difference in the number of
ARs or in the types of ARs between the 2 treatment groups, except
for nausea (grade 1), a common AR due to doxycycline intake.
Sustained Reduction of Microﬁlarial Skin Loads in the
Doxycycline Group
At baseline, there was no signiﬁcant difference in the microﬁlar-
ial load (median Mf/mg skin) between treatment groups
(Table 2, all cohorts). However, at 12 months, a signiﬁcant dif-
ference appeared (P < .001), with the doxycycline group show-
ing medians of 0, whereas the placebo group’s medians
increased throughout all cohorts. This difference was main-
tained at 20 months after treatment (P < .001).
Of the 87 study participants who completed the treatment PP
and received 2 rounds of IVM during the course of the trial
(treatment and IVM-PP), 49.4% were microﬁlaridermic (Mf
positive) at study entry. At the 12-month follow-up time
point, only 1 of 40 individuals (2.5%) in the doxycycline treat-
ment group remained microﬁlaridermic, indicating a signiﬁcant
drop after treatment. In contrast, 24 of 44 patients (54.5%) in
the placebo group remained Mf-positive despite 1 additional
round of IVM (P < .001). Importantly, even after 2 additional
rounds of IVM at the 20-month follow-up, 34.1% of individuals
in the placebo group were persistently Mf positive.
In the ITT dataset, a few more patients in the doxycycline treat-
ment arm remained microﬁlaridermic, consistent with the fact
that 13 patients did not complete the doxycycline regimen. Inter-
estingly, in the PP dataset, 7 of 69 patients were still Mf positive
after 12 months, whereas this number dropped to 2 of 67 patients
after 20 months, consistent with a block in new embryo produc-
tion and therefore slow decay of Mf in the absence of IVM.
In summary, the Mf data reﬂect the long-term sterilization of
O. volvulus after treatment with doxycycline, whereas fertility of
female worms was not reduced in placebo patients. The results
from the placebo group are of particular concern, as despite 2
additional rounds of IVM, Mf positivity still remained prevalent
in this group.
Doxycycline Inhibits Embryogenesis and Has Macroﬁlaricidal
Activity
All the histological analyses were performed according to PP
analysis—that is, included only those individuals who had com-
pleted doxycycline/placebo treatment and adhered to the 20-
month follow-up. Worms were classiﬁed as having many, few,
or no Wolbachia (Table 3), as described previously [15]. Eighty
percent of the female worms in the placebo group wereWolbachia
positive (few and many), whereas only 5.1% containedWolbachia
in the doxycycline-treated group (P < .001). A similar difference
was observed for male worms.
When investigating for embryogenesis, we found that, in ac-
cordance to our earlier study [15], 53% of female worms in the
placebo group had normally developed embryos at 20 months,
and Mf were observed in 30.7% of the nodules analyzed
(Table 4). In contrast, only 3.8% female worms from the doxy-
cycline group exhibited normal embryogenesis, and none of the
152 nodules were Mf positive. In addition to the inhibition of
embryogenesis, we also observed a signiﬁcant reduction in the
insemination of the female worms in this group (Table 4).
The doxycycline group showed a signiﬁcant increase in dead
female worms at 20 months compared with the placebo group
(Table 5; P < .001). A trend toward a higher percentage of dead
males in the doxycycline-treated group was also seen (P = .136);
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the variability may be due to the observation that dead males are
more quickly absorbed than females [20]. The age pattern of the
worm population did not reveal signiﬁcant differences between
the treatment groups (Table 6).
Table 7 shows the average numbers of sites and nodules, pal-
pated at study entry and at 20 months prior to nodulectomy, as
well as the actually ectomized and evaluated nodules. There was a
greater reduction in the number of palpated nodules in the dox-
ycycline group over the observation period compared with the
placebo group (P = .015). These data suggest that dead worms
are absorbed over time and that the macroﬁlaricidal effect of dox-
ycycline may even have been greater than detected by histology.
Additional Statistical Analyses
In addition to the PP analysis, we reanalyzed the data using the
ITT data set. Table 8 shows in summary that even under ITT
conditions, all parameters compared were still signiﬁcant, this
being the case at the level of the worm itself as well as with
the total sum of the worms present per patient. Details on the
ITT dataset for presence of Wolbachia, embryogenesis, and
worm killing can be found in Supplementary Tables 2–5.
Because the worms within one patient could not, a priori, be
regarded as independent (for example, they aggregate in nod-
ules and this may facilitate their survival, and doxycycline
may have had different bioavailability in different patients), we
Table 2. Microﬁlarial Densitiesa
Study Time Point
ITT (n = 167) Treatment-PP (n = 147) Treatment and-IVM-PP (n = 87)
Doxycycline Placebo Doxycycline Placebo Doxycycline Placebo
Baseline
Mf positive 47/84 (56.0%) 48/83 (57.8%) 40/71 (56.3%) 43/76 (56.6%) 20/42 (47.6%) 23/45 (51.1%)
P valueb P= .876 P= 1.0 P= .831
Mean ± SD 2.30 ± 6.29 3.23 ± 8.69 1.90 ± 4.35 3.46 ± 9.05 0.84 ± 2.66 3.27 ± 10.51
GMc 0.78 1.03 0.75 1.08 0.4 0.82
Min–Max 0–45.62 0–65.99 0–24.87 0–65.99 0–17.02 0–65.99
Median 0.15 0.26 0.14 0.27 0 0.13
25th, 75th percentiles 0, 1.11 0, 1.94 0, 1.11 0, 2.00 0, 0.63 0, 0.97
P valued P= .495 P= .544 P= .498
12 mo
Mf positive 8/73 (11.0%) 44/72 (61.1%) 7/69 (10.1%) 42/70 (60.0%) 1/40 (2.5%) 24/44 (54.5%)
P valueb P< .001 P< .001 P< .001
Mean ± SD 0.87 ± 3.74 4.50 ± 8.11 0.90 ± 3.85 4.33 ± 8.10 0.70 ± 4.43 4.01 ± 7.24
GMc 0.21 1.68 0.21 1.58 0.09 1.47
Min–Max 0–28.00 0–38.63 0–28.00 0–38.63 0–28.00 0–33.86
Median 0 0.96 0 0.81 0 0.52
25th, 75th percentiles 0, 0 0, 4.50 0, 0 0, 4.11 0, 0 0, 5.71
P valued P< .001 P< .001 P< .001
20 mo
Mf positive 5/76 (6.6%) 50/74 (67.6%) 2/67 (3.0%) 47/70 (67.1%) 1/42 (2.4%) 27/45 (60.0%)
P valueb P< .001 P< .001 P< .001
Mean ± SD 0.75 ± 4.57 3.99 ± 9.05 0.56 ± 4.35 3.88 ± 9.12 0.85 ± 5.49 1.87 ± 4.24
GMc 0.12 1.35 0.07 1.29 0.09 0.83
Min–Max 0–35.60 0–46.58 0–35.60 0–46.58 0–35.60 0–24.46
Median 0 0.65 0 0.52 0 0.21
25th, 75th percentiles 0, 0 0, 2.91 0, 0 0, 2.41 0, 0 0, 1.24
P valued P< .001 P< .001 P< .001
Persistently Mf positivee 1/69 (1.4%) 24/69 (34.8%) 0/65 (0%) 24/68 (35.3%) 0/40 (0%) 15/44 (34.1%)
Abbreviations: GM, geometric mean; ITT, intention to treat; IVM, ivermectin; Mf, microfilariae; PP, per protocol; SD, standard deviation.
a The ITT set includes all patients who received the study drugs for at least 1 day. The Treatment-PP set includes all people who took the treatment according to
protocol and on this basis another set was created, only including people who also took part in both rounds of mass drug administration between treatment and 20
months of follow-up (Treatment and IVM-PP).
b Fisher exact test.
c The GM was calculated by adding 1 to all values and after the calculation 1 was again subtracted from the result.
d Mann–Whitney U test.
e Number of participants who were persistently Mf positive over all 3 timepoints.
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used alternating logistic regression to account for within-patient
dependence (Table 8); despite the additional factor, results
remained signiﬁcant.
It was observed that the mean age differed between the treat-
ment groups, which randomly occurred during the randomiza-
tion process. Although multiple regression analysis did not
show any inﬂuence of the patient’s age on most of the histolog-
ical outcome variables, it revealed different age effects in the
treatment groups regarding the occurrence of dead worms
(Supplementary Figure 2). A higher age in the placebo group
was associated with an increased likelihood for dead worms
(odds ratio [OR], 1.0771; P = .005), but this age effect was no
longer present in the doxycycline group (OR, 1.0092; P = .5775).
DISCUSSION
There is now a consensus that chemotherapies beyond mono-
therapy with IVM are urgently needed for onchocerciasis. A
number of situations and challenges underscore this reality:
(1) individual cases presenting to doctors need to be given the
best available treatment; (2) in Loa loa–coendemic areas, pa-
tients coinfected with loiasis with Loa Mf loads >8000 Mf/mL
run a risk of developing serious, even fatal, neurologic reactions
when treated with IVM as part of onchocerciasis MDA [21, 22];
(3) new agents are also needed should IVM resistance, or indeed
any other form of SOR, occur.
The use of doxycycline fulﬁlls these criteria for situations 1
and 2 for onchocerciasis. In situation 1, doxycycline’s macroﬁ-
laricidal and long-term sterilizing activities render it a disease-
curing choice for individual treatment, different to IVM, which
will have to be repeated for years until the adult worms have ter-
minally stopped embryogenesis [16]. The treatment recommen-
dation here has been to administer 1 course of doxycycline
followed by 1 round of IVM, to combine the sterilizing and kill-
ing effects of doxycycline on the female worms with the rapid
killing of skin Mf by IVM [23].
In situation 2, recent consensus is to identify areas with a like-
lihood for coinfected individuals with high counts for L. loaMf,
Table 3. Effect of Doxycycline Treatment on Presence of Wolbachia in Worms
Treatment Group Time, mo No. of Patients/ Nodulesa
No. of Living Female Wormsb No. of Living Male Wormsb
Allc
With Wolbachiad
Allc
With Wolbachiad
Many Few None Many Few None
Doxycycline (6 wk) 20 56/152 117 1 5 111 41 0 3 36
Placebo 20 63/199 184 60 80 35 54 5 19 26
a Only evaluable patients/nodules are included; nodules with newly acquired worms only are subtracted.
b Newly acquired worms were subtracted (doxycycline, n = 8 females; placebo, n = 7 females).
c Although the number of all living worms is given to make the numbers consistent to the other tables, in 15worms, it was not possible to distinguish if theworm had
many, few, or no Wolbachia, due to too little worm material in the respective histological sections. Therefore, “All” is not always a summary of the 3 categories.
d Significant difference between the doxycycline and the placebo group regarding absence ofWolbachia (bP < .001 for female and male worms respectively, Fisher
exact test).
Table 4. Effect of Doxycycline Treatment on Embryogenesis
Treatment
Group
Time,
mo
No. of Patients/
Nodulesa
No. of Living Female Wormsb No. of Nodules
All
Embryosc
Sperms in
Uterusd All
With Intact
Microfilariaee
Not
Judgeable
Uterus Empty,
Oocytes Only Normal Degenerated
Doxycycline
(6 wk)
20 56/152 117 13 93 4 7 9 152 0
Placebo 20 63/199 184 16 76 89 3 54 199 61
a Only evaluable patients/nodules are included; nodules with newly acquired worms only are subtracted.
b Newly acquired worms were subtracted (doxycycline, n = 8 females; placebo, n = 7 females).
c Significant difference between the doxycycline and the placebo group regarding the presence of normal vs degenerated embryogenesis (P < .001, Fisher exact
test).
d Significant difference between the doxycycline and the placebo group regarding the number of worms found with sperms within the uterus (P < .001, Fisher exact
test).
e Significant difference between the doxycycline and the placebo group regarding the proportion of nodules with intact microfilariae (P < .001, Fisher exact test).
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and then to test (eg, with cell phone–based microscopy) all in-
dividuals in such areas and exclude those with >30 000 Mf/mL
from IVM treatment [24]. However, those individuals can be
treated safely with doxycycline to kill their O. volvulus parasites,
as L. loa does not contain Wolbachia. In their 2013 annual
meeting in Brazzaville, the Joint Action Forum, APOC’s gov-
erning board, has adopted the use of doxycycline for treatment
of individual patients (http://www.who.int/apoc/Journal_
ENGLISH_Day_3_FINAL_red.pdf ).
The present study delivers formal proof that doxycycline,
given at 100 mg/day for 6 weeks, is also suitable for situation
3, in areas with SOR. This dose interrupted embryogenesis
for at least 20 months, whereas the placebo group did not
clear skin Mf even after receiving 2 additional doses of IVM;
this latter group is typical of the SOR to IVM observed previ-
ously [11, 12, 17, 18]. Previous investigations in our study area
have suggested that the presence of fertile female worms 3–6
months after the last of at least 9 rounds of IVM is inconsistent
with a normal response to IVM [11, 12, 17, 18]. The results from
the placebo group in our study underscore this further, while
the doxycycline regimen delivers a safe “ready-to-go” approach
for O. volvulus worms suspected of showing SOR to IVM. Com-
munity trials in our study area are currently addressing the
impact of a test-and-treat strategy, using doxycycline in com-
munities where SOR to IVM has been observed.
Doxycycline did not provoke a different level of ARs com-
pared with the placebo group.
As opposed to the only known macroﬁlaricide suramin [25],
the low toxicity of doxycycline is probably due to its relatively
slow-acting effect on the worms, leading to a protracted death
after more than a year [15, 26], ensuring that the host is able to
handle the events occurring during the killing of the adults; as a
consequence, severe ARs do not occur. The slow macroﬁlarici-
dal action of the drug, however, brings about an issue regarding
monitoring in clinical trials if they take place in endemic areas.
Although a 100% macroﬁlaricidal activity of doxycycline would
probably be achieved, as model estimates go [27], this cannot be
directly observed in trials because with observation periods >1.5
years, there is confounding interference from new incoming
worms in geographical areas such as our study site, where infec-
tion transmission has not yet been interrupted [4, 15].
In the present trial, the proportion of dead worms analyzed
in the available nodules after doxycycline was 54% (PP). A daily
dose of “only” 100 mg/day as opposed to 200 mg/day [15] prob-
ably does not account for a lower number of dead worms, as
new modeling data suggest that regardless of the daily dose,
the average life span of a worm is reduced from the normal
10 years’ average to 2 years after exposure to doxycycline for
4–6 weeks [28].
In addition, the actual macroﬁlaricidal rate was probably high-
er as we observed a loss of nodules between pretreatment and
Table 5. Macroﬁlaricidal Effect of Doxycycline Treatment
Treatment
Group
Time,
mo
No. of
Patients/
Nodulesa
No. of Female
Wormsb
No. of Male
Wormsb
All
Dead
Femalesc
(%) All
Dead
Males
(%)
Doxycycline
(6 wk)
20 56/152 253 136 (54%) 50 9 (18%)
Placebo 20 63/199 300 116 (39%) 58 4 (7%)
a Only evaluable patients/nodules are included; nodules with newly acquired
worms only were subtracted.
b Newly acquired worms were subtracted (doxycycline, n = 8 females; placebo,
n = 7 females).
c Significant difference between the doxycycline and the placebo group
regarding the proportion of dead female worms (P < .001, Fisher exact test).
Table 6. Age Pattern of Wormsa
Treatment Group
Time,
mo
No. of Patients/
Nodulesb
No. of Living Female Worms No. of Living Male Worms
All
Age
Allc
Age
Newly
Acquired Young Middle Old
Newly
Acquired Young Middle Old
Doxycycline
(6 wk)
20 56/157 125 8 12 48 57 41 0 2 27 10
Placebo 20 63/205 191 7 30 73 81 55 1 2 34 17
a Characteristics for the age of aworm included loss of body wall integrity, loss of nuclei of all organs, and absence of aspartic protease (APR) staining. Very degenerated
worms, still APR positive, were classified as moribund and grouped in the category “dead.” Older worms were larger and presented degenerated tissues. Gomori iron
stain showed that the worms accumulated more iron with increasing age, first in the gut and later in other organs. Using an antibody against O. volvulus lysosomal
aspartic protease, the gut of young worms was stained only weakly, whereas it was stronger in older worms, accompanied by additional staining of hypodermis and
epithelia. These criteria as well as morphological findings (diameter, position within the nodule) were used to discriminate newly acquired worms [4, 15].
b Only evaluable patients/nodules are included. In contrast to Tables 4–6, newly acquired worms are included.
c In 3 male worms, it was not possible to distinguish the age pattern of the worm in the respective histological sections. Therefore, “All” is not always a summary of
the 4 categories.
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20 months in the doxycycline group. Taking into account that
about 0.4 nodules per patient were lost in this group (Table 7),
with an average of about 1.5 female worms per nodule (Table 5),
one would have to include approximately 30 more dead female
worms to the death toll, raising the ratio to approximately
59%. Interestingly, it has been observed that the size of
Table 7. Palpated, Operated, and Evaluated Nodules and Sitesa
Study Time Point
No. of Nodules No. of Sites
Doxycycline Placebo Doxycycline Placebo
Baseline
No. of patients 71 76 71 76
Total No. of nodules/sites 178 182 114 116
Mean ± SD 2.51 ± 1.40 2.39 ± 1.86 1.61 ± 0.78 1.53 ± 0.81
Min–Max 1–6 1–11 1–4 1–4
Median 2 2 1 1
25th, 75th percentiles 1, 3 1, 3 1, 2 1, 2
P valueb P= .151 P= .378
20 mo
No. of patients 67 69 67 69
Total No. of nodules/sites 137 150 98 104
Mean ± SD 2.04 ± 1.32 2.17 ± 1.68 1.46 ± 0.68 1.51 ± 0.87
Min–Max 1–6 0–8 1–4 0–4
Median 2 2 1 1
25th, 75th percentiles 1, 3 1, 2 1, 2 1, 2
P valueb P= .858 P= .903
Difference 20 mo – baseline
No. of patients 67 69 67 69
Mean ± SD −0.43 ± 1.03 −0.09 ± 1.00 −0.12 ± 0.54 0.01 ± 0.56
Min–Max −5 to 2 −4 to 2 −1 to 1 −2 to 1
Median 0 0 0 0
25th, 75th percentiles −1, 0 0, 0 0, 0 0, 0
P valueb P= .015 P= .109
Operatedc
No. of patients 66 66 66 66
Total No. of nodules/sites 182 227 99 108
Mean ± SD 2.76 ± 2.18 3.44 ± 2.79 1.5 ± 0.75 1.64 ± 0.97
Min–Max 1–13 1–14 1–4 1–5
Median 2 2.5 1 1
25th, 75th percentiles 1, 3 2, 4 1, 2 1, 2
P valueb P= .126 P= .591
Evaluatedd
No. of patients 56 63 56 63
Total No. of nodules/sites 152 199 79 97
Mean ± SD 2.71 ± 2.02 3.16 ± 2.39 1.41 ± 0.73 1.54 ± 0.84
Min–Max 1–11 1–12 1–4 1–4
Median 2 2 1 1
25th, 75th percentiles 1, 3 2, 4 1, 2 1, 2
P valueb P= .277 P= .412
Abbreviation: SD, standard deviation.
a The set used here (Treatment-per protocol) includes all people who took the treatment (doxycycline or placebo) according to protocol.
b Mann–Whitney U test.
c In 4 participants, no nodule was found before or after incision.
d Thirteen participants and, in total, 11.5% (n = 47) of all nodules could not be analyzed for parasitic status; the reasons for this exclusion included extensive
calcification of the nodule, or being of nononchocercal origin (eg, foreign body granulomas, lipomas, or lymph nodes). An additional 11 nodules were subtracted
for containing newly acquired worms only.
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Onchocerca ochengi nodules is signiﬁcantly reduced after tetracy-
cline treatment in cattle and indicates absorption of the nodules
[29].
The ultimate cause of the SOR to IVM is as yet unknown. Al-
though selection of resistance genes has been discussed [30–33],
and evidence of allele selection could indeed be documented
from worms of our study area, there are other potential mech-
anisms, such as adaptation of the worms’ biology (eg, change in
transcription levels as opposed to gene mutation), or even im-
munological facilitation by the host. Along these lines, we have
observed that the level of TGF-β detectable in host cells around
female worms in nodules are associated with the rounds of IVM
[34]. If these preliminary data hold for other areas, this type of
SOR may become much more frequently observed and will re-
quire adequate therapeutic approaches, such as killing adult
worms or sterilizing them permanently. This study shows that
doxycycline treatment fulﬁlls these requirements.
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